Health & Biotech
Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, where there is persistent neuroinflammation. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company commenced Phase II/III randomised, double-blind, placebo controlled clinical trial in ASD in Q4 CY2022. Neurotech is also conducting additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome and Cerebral Palsy during CY2023.
NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (M<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN.
NTI164 has been exclusively licenced for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Stockhead TV
V-Con: Talking medical innovations and breakthrough treatments with ASX biotechs
Health & Biotech
Neurotech hits another key milestone with unique drug therapy in the US$25bn market for multiple sclerosis treatments
Health & Biotech
Budget review: Here’s what ASX biotech players thought of the ‘patent box’
Health & Biotech
Neurotech just started world’s first THC-less cannabis study in autistic children
Health & Biotech
Neurotech makes significant progress with world’s first cannabidiol drug for children with autism
Health & Biotech
Hot Pot Stocks: Here are 8 ASX plays that have tripled in the last 12 months
News
Last Orders: Small caps gain but tech, BNPL selloff continues
Health & Biotech
Huge potential for tiny Perth company’s autism treatment candidate
Health & Biotech
Neurotech gains after company prepares to begin first-in-human clinical trials
News
Check Up: Creso Pharma gets really, really high; leads ASX health sector
News
Tech space has its day in Perth sun
News
Last Orders: What you might have missed on the ASX today
Health & Biotech
Lab tests confirm neuro-protective potency of Neurotech’s unique strains of cannabis
Health & Biotech
Weed Week: All eyes on the TGA after key decision pushed back to December
Stockhead TV
Why Australia’s medicinal cannabis has the leading edge
Health & Biotech
Neurotech gets new chairman, makes pivot to cannabis space official
Health & Biotech